Korean National Health Insurance data compared the risk of CV events in 39,640 gout pts starting allopurinol or febuxostat. MACE incidence was 1.89 vs 1.84/100PY (HR 1.09; 0.90, 1.32) Thus, no significant difference in CV risk with these agents in Asians https://t.co/l316siAqd8